Figure 1.

Recombinant anthrax lethal toxin inhibits the MAPK pathway without affecting cell viability in astrocytoma. (A) SF268 cells were treated either with the recombinant anthrax lethal toxin or the MEK inhibitor U0126 for 2 h. Cells were lysed and immunoblotted by western blot analysis for p-ERK (upper gel) or ERK (lower gel) for loading control. Quantitation represents three different blots from three independent experiments. (B) The effect of LeTx on cell viability was tested using an MTT assay as mentioned in Materials and methods. The graph is a non-linear regression curve of LeTx on human SF-268 cell lines.